Delivery Order SPE2DB20D1110-SPE2DB25FJ82X

Award Date 12/15/24
Potential Completion Date 12/16/24
Potential Value $3.6K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $6,771.19, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of REXULTI 1 MG TABLET 30S, a pharmaceutical product, with a performance period through June 10, 2024. The award is a Delivery Order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999...
This federal contract award, valued at $7,752.48, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the supply of REXULTI 0.5 MG TABLET 30S, a pharmaceutical product. The contract has a firm fixed price pricing type and an ultimate completion date of November 29, 2023. This award is a part of a larger Indefinite Delivery Contract (IDC) held by...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $14,891.25 delivery order contract is for the supply of REXULTI 3 MG TABLET 30S, a pharmaceutical product. The contract has an ultimate completion date of January 8, 2025 and is a firm fixed-price delivery order. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen...
This federal contract award, valued at $1,951.74, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of REXULTI 2 MG TABLET 30S, a pharmaceutical product, with a completion date of January 3, 2025. This contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,853.61 firm fixed-price delivery order is for the supply of REXULTI 0.5 MG TABLET 30S, a pharmaceutical product. The contract has an ultimate completion date of October 21, 2024. The award is associated with a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical,...
This federal contract award, valued at $25,573.11, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of REXULTI 0.5 MG TABLET 30S, a pharmaceutical product. This is a firm fixed-price delivery order contract with a completion date of January 13, 2025. The contract is not designated as a set-aside. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, which has a ceiling value of $56,834.34, is for the delivery of REXULTI 2 MG TABLET 30S, a pharmaceutical product. The contract is a Firm Fixed Price Delivery Order with a completion date of July 3, 2024. The award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,887.69 firm fixed-price delivery order is for the supply of REXULTI 3 MG TABLET 30S, a pharmaceutical product. The contract has an ultimate completion date of July 15, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
This federal contract award is a delivery order valued at $2,584.79 issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of REXULTI 1 MG TABLET 30S, a pharmaceutical product, with a period of performance through December 18, 2024. The contract is a firm fixed-price arrangement and does not have a set-aside designation, indicating open competition. AmerisourceBergen...
This federal contract award, valued at $6,301.90, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of REXULTI 1 MG TABLET 30S, a pharmaceutical product, with a period of performance through March 18, 2025. The contract is a Delivery Order with a Firm Fixed Price pricing type and does not have a set-aside designation, indicating open competition. AmerisourceBergen...
  • SPE2DB20D1110
    Indefinite Delivery Contract
  • SPE2DB20D1110-SPE2DB25FJ82X
    Delivery Order

This federal contract award, valued at $3,552.76, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of REXULTI 1 MG TABLET 30S, a pharmaceutical product, with a completion date of December 16, 2024. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract award did not have a set-aside designation, indicating open competition.

Generated 5/20/25, 2:32 PM